132715-74-3

Upstream product

• 620550-97-2 diethyl 2-[(2-fluoro-6-nitro-phenyl)methyl]propanedioate 
• 1958-93-6 2-(bromomethyl)-1-fluoro-3-nitrobenzene 

Downstream Products

• 116434-95-8 5-fluoro-3,4-dihydro-1H-quinolin-2-one 
• 132715-59-4 3-(2-Fluoro-6-nitro-phenyl)-N,N-dimethyl-propionamide 
• 132715-75-4 N,N-Dimethyl-3-(2-amino-6-fluorophenyl)propanamide 
• 132715-58-3 3-(2-Fluoro-6-nitro-phenyl)-propionyl chloride 

Relevant academic research and scientific papers

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS

The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

FUSED LACTAM COMPOUNDS

This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or

3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The com

Synthetic Entries to 6-Fluoro-7-substituted Indole Derivatives

Three practical synthetic entries of functionalized 6-fluoro-7-substituted indole derivatives were developed in connection with the preparation of 7-fluoro-8-substituted-1,3,4,9-tetrahydropyranoindole-1-acetic acid derivatives 11.The first route, w